Therapeutic Antibody Development for Stroke

Antibody drugs for the treatment of stroke have attracted considerable attention from the scientific community. There is growing evidence that targeting endogenous molecules or signaling cascades with monoclonal antibodies can reduce the severity of injury or completely heal damaged brain tissue. Antibody-based therapies offer a novel adjunct to stroke treatment. Many molecules have been targeted for stroke therapy and many antibodies have been developed. These molecules are primarily located on cell membranes or in the extracellular space, where they can be targeted by antibodies.

Fig. 1. Antibody-based therapies offer a new type of adjuvant stroke treatment. Fig. 1. Schematic representative diagram demonstrating intravenous or subcutaneous injection of different forms of antibody-based medications to a stroke patient. (Sun et al., 2022)

Our Therapeutic Antibody Development Services

As a CRO service provider focused on stroke, Ace Therapeutics helps clients develop safe and effective therapeutic antibodies. Our comprehensive services cover the full spectrum of therapeutic antibody development, from initial target identification and antibody discovery to preclinical evaluation.

Using our extensive expertise in hybridoma technology, phage display and single-cell sequencing, we help clients to generate a broad range of high-affinity, specific antibodies that selectively modulate key molecular pathways involved in stroke pathogenesis.

Types of Therapeutic Antibodies We Can Develop

Ace Therapeutics identifies and validates multiple molecules as targets and provides one-stop therapeutic antibody development services for stroke.

Improving the Efficacy of Therapeutic Antibodies

Strategies	Service Details
Custom Antibody Engineering	Our skilled engineers use advanced techniques such as Fc engineering and antibody humanization to fine-tune the structural and functional characteristics of therapeutic antibodies. We can extend their half-life, improve BBB permeability, and enhance their ability to trigger desired biological responses in the ischemic brain microenvironment.
Cell Receptor-mediated Strategies	We make antibodies reach the brain using cellular receptor-mediated strategies. This strategy utilizes certain BBB enriched receptors, such as transferrin receptor (TfR), insulin receptor (IR), and diphtheria toxin receptor (DTR), which can be potentially conjugated to increase the ability of receptor-mediated transport of antibodies into the brain.
Antibody-Drug Conjugates	We modify the surface of drug-carrying nanoparticles by binding them to brain-specific antibodies. These antibody-drug conjugates recognize specific ligands and act as stroke therapeutics through receptor-mediated endocytosis across the BBB.
Single-domain Antibodies	We develop single-domain antibodies to be used as carriers for the transport of antibodies across the BBB. In addition, we develop therapeutic single-domain antibodies that improve the BBB and tissue permeability and contribute to surface modifications for site-specific targeting.

Why Choose Us

We have a thorough understanding of the multiple signaling pathways following stroke injury to help clients rationally plan immunotherapy targets and intervention points. Our experts work closely with our clients to carefully design and evaluate animal experiments to fully understand possible side effects following immunotherapy.
We offer stroke immunotherapy studies, including active immunization with peptide inoculation and passive immunization with direct injection of antibodies into animals.
We have well-established animal models of stroke to study the efficacy and safety of targeted antibodies to maximize the therapeutic effect of monoclonal antibodies. We also support the study of the therapeutic effects of multiple antibody combinations.
We offer multiple strategies to enhance BBB permeability to improve antibody-based therapy in the brain.

Ace Therapeutics aims to help clients accelerate the development of therapeutic antibodies for stroke. Our team collaborates with academic and pharmaceutical partners to design and execute well-controlled preclinical studies. Please fell free to contact us. We look forward to working with you!

Reference

Sun, J. M., et al. (2022). Advances in antibody-based therapeutics for cerebral ischemia. Pharmaceutics, 15(1), 145.

All of our services are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.